2m 2m 2m 2m 2m 2m 2m
- $3.5MMarket Cap
- N/A1-Year Change
- Medical DevicesIndustry
20/20 BIOLABS (AIDX)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
20/20 BioLabs announced a rescheduled investor webinar for September 2, 2026 at 2:00 p.m. ET to discuss Q2 2026 results featuring record OneTestâ„¢ revenue of $0.7 million (47.1% YoY increase), gross margin expansion to 41.7%, and commercial expansion across multiple channels including firefighter cancer screening programs.
08/28/2026, 6:26 PM • GlobeNewswire
20/20 BioLabs (Nasdaq: AIDX) announced the launch of a recurring monthly investor webinar series starting July 1, 2026, held on the first Wednesday of each month at 12:00 p.m. ET. The initiative aims to increase transparency, strengthen shareholder communication, and provide direct access to management regarding the company's AI-powered blood tests for early cancer detection and chronic disease prevention.
06/22/2026, 4:45 PM • GlobeNewswire
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
20/20 BioLabs (Nasdaq: AIDX) reported FY 2025 revenue of $2.0 million, up 17% year-over-year, with gross profit increasing 68% and gross margin expanding 900 basis points to 29.6%. The company achieved a 33% improvement in net loss to $3.7 million and reduced operating expenses by 35%. Recent highlights include a $5.0 million funding round, Nasdaq listing, $520,000 in Maryland state funding for firefighter cancer screenings, and launch of OneTest for Longevity. Management expects 2026 to be a breakout year driven by strong demand across firefighting, veterans, and occupational health markets.
03/31/2026, 4:57 PM • GlobeNewswire
Peers
No data found
Statistics
MoreInformation as of 10/21/2026
Company Profile
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Key Executives
- Jonathan Cohen
- Jiming Zhou
- Michael S. Lebowitz
- Marc Gordon
- David Lees
Current Ownership Distribution
- Other11.3M (88.61%)
- Institutions841,045 (6.59%)
- Insiders602,936 (4.72%)
- Mutual Funds10,638 (0.08%)